In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Telemedicine is yet to overcome diversity challenges in dermatology clinical trials
This article explores the benefits and challenges of telemedicine in dermatology clinical trials.
Clinical Trials Arena
-
Irish healthcare company ICON posted $800m in profits
In this interview on Newstalk Breakfast Business, Steve Cutler, CEO, is interviewed by Joe Lynam.
-
ICON shares soar as it posts double digit profit growth for the first half of 2023
This article from the Business Post covers ICON’s Q2 2023 financial results, reporting that the company recorded double-digit profit growth for the first half of the year on the back of increased contract wins.
-
ICON's quarterly revenues
This article from RTE reports on ICON’s Q2 2023 financial results and features an interview with Steve Cutler, CEO, ICON.
© RTÉ 2023
-
AI poised to revolutionise drug development
AI is poised to revolutionise drug development. ICON’s Chief Medical and Innovation Officer, Greg Licholai, explores this topic in his recent column in Forbes.
-
ICON Cares 2022 ESG Report
Diarmaid Cunningham, Chief Administrative Officer, discusses ICON’s 2022 ESG Report in Drug Discovery World.
Copyright 2023 © Drug Discovery World (DDW)
-
Essential considerations for a successful submission under EU CTR
A key feature of the EU CTR is the introduction of a single electronic portal, the Clinical Trial Information System (CTIS), which is mandatory for all EU CTR submissions. CTIS enables harmonised and simplified end-to-end electronic application procedures over the lifecycle of clinical trials across the EU/EEA.
Published by International Biopharmaceutical Industry Journal Volume 6 Issue 2
-
Comparing treatment performance through evidence synthesis
If there is a variety of treatment options in a specific disease area, decision makers require evidence of efficacy and safety of novel interventions in comparison to established treatments. One randomised controlled trial (RCT) is not sufficient to come to a final conclusion, especially since RCTs often present contradictory results.
Published by Journal for Clinical Studies Volume 15 Issue 2 (https://journalforclinicalstudies.com/).
-
Accessibility in rare disease paediatric clinical trials
In this International Pharmaceutical Industry article, ICON experts Kirsten Sherman Cervati and William C. Maier discuss strategies to make clinical trials more accessible for Paediatric patients and their families.
-
Clinical translation and linguistic validation at scale
Senior Vice President of Commercialisation & Outcomes, Brian Mallon, joins SlatorPod to shed light on the crucial role of language services within clinical research organisations.
